Filtered By:
Source: Uirusu. Journal of Virology
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 830 results found since Jan 2013.
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Uirusu. 2021;71(1):41-44. doi: 10.2222/jsv.71.41.NO ABSTRACTPMID:35526993 | DOI:10.2222/jsv.71.41
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Takeshi Arashiro Tadaki Suzuki Source Type: research
Genomics and epidemiology of SARS-CoV-2 lineage
Uirusu. 2021;71(1):19-32. doi: 10.2222/jsv.71.19.ABSTRACTCoronavirus disease 2019（COVID-19）is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）．It had been first identified in Wuhan at the end of 2019 and the spread of SARS-CoV-2 variants has become a crucial issue worldwide. WHO categorized SARS-CoV-2 variants as "Variants of Concern; VOCs" and "Variants of Interest; VOIs" based on transmissibility, disease severity or their susceptibility to vaccines. Especially, the spread of SARS-CoV-2 variant categorized in VOCs, such as B.1.1.7 and B.1.617.2, has...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Sayaka Sukegawa Hiroaki Takeuchi Source Type: research
Dengue amidst COVID-19: challenges & amp; control measures for the double burden
Uirusu. 2021;71(1):1-10. doi: 10.2222/jsv.71.1.ABSTRACTDengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interv...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Meng Ling Moi Source Type: research
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Uirusu. 2021;71(1):41-44. doi: 10.2222/jsv.71.41.NO ABSTRACTPMID:35526993 | DOI:10.2222/jsv.71.41
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Takeshi Arashiro Tadaki Suzuki Source Type: research
Genomics and epidemiology of SARS-CoV-2 lineage
Uirusu. 2021;71(1):19-32. doi: 10.2222/jsv.71.19.ABSTRACTCoronavirus disease 2019（COVID-19）is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）．It had been first identified in Wuhan at the end of 2019 and the spread of SARS-CoV-2 variants has become a crucial issue worldwide. WHO categorized SARS-CoV-2 variants as "Variants of Concern; VOCs" and "Variants of Interest; VOIs" based on transmissibility, disease severity or their susceptibility to vaccines. Especially, the spread of SARS-CoV-2 variant categorized in VOCs, such as B.1.1.7 and B.1.617.2, has...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Sayaka Sukegawa Hiroaki Takeuchi Source Type: research
Dengue amidst COVID-19: challenges & amp; control measures for the double burden
Uirusu. 2021;71(1):1-10. doi: 10.2222/jsv.71.1.ABSTRACTDengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interv...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Meng Ling Moi Source Type: research
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Uirusu. 2021;71(1):41-44. doi: 10.2222/jsv.71.41.NO ABSTRACTPMID:35526993 | DOI:10.2222/jsv.71.41
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Takeshi Arashiro Tadaki Suzuki Source Type: research
Genomics and epidemiology of SARS-CoV-2 lineage
Uirusu. 2021;71(1):19-32. doi: 10.2222/jsv.71.19.ABSTRACTCoronavirus disease 2019（COVID-19）is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）．It had been first identified in Wuhan at the end of 2019 and the spread of SARS-CoV-2 variants has become a crucial issue worldwide. WHO categorized SARS-CoV-2 variants as "Variants of Concern; VOCs" and "Variants of Interest; VOIs" based on transmissibility, disease severity or their susceptibility to vaccines. Especially, the spread of SARS-CoV-2 variant categorized in VOCs, such as B.1.1.7 and B.1.617.2, has...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Sayaka Sukegawa Hiroaki Takeuchi Source Type: research
Dengue amidst COVID-19: challenges & amp; control measures for the double burden
Uirusu. 2021;71(1):1-10. doi: 10.2222/jsv.71.1.ABSTRACTDengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interv...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Meng Ling Moi Source Type: research
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Uirusu. 2021;71(1):41-44. doi: 10.2222/jsv.71.41.NO ABSTRACTPMID:35526993 | DOI:10.2222/jsv.71.41
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Takeshi Arashiro Tadaki Suzuki Source Type: research
Genomics and epidemiology of SARS-CoV-2 lineage
Uirusu. 2021;71(1):19-32. doi: 10.2222/jsv.71.19.ABSTRACTCoronavirus disease 2019（COVID-19）is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）．It had been first identified in Wuhan at the end of 2019 and the spread of SARS-CoV-2 variants has become a crucial issue worldwide. WHO categorized SARS-CoV-2 variants as "Variants of Concern; VOCs" and "Variants of Interest; VOIs" based on transmissibility, disease severity or their susceptibility to vaccines. Especially, the spread of SARS-CoV-2 variant categorized in VOCs, such as B.1.1.7 and B.1.617.2, has...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Sayaka Sukegawa Hiroaki Takeuchi Source Type: research
Dengue amidst COVID-19: challenges & amp; control measures for the double burden
Uirusu. 2021;71(1):1-10. doi: 10.2222/jsv.71.1.ABSTRACTDengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interv...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Meng Ling Moi Source Type: research
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Uirusu. 2021;71(1):41-44. doi: 10.2222/jsv.71.41.NO ABSTRACTPMID:35526993 | DOI:10.2222/jsv.71.41
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Takeshi Arashiro Tadaki Suzuki Source Type: research
Genomics and epidemiology of SARS-CoV-2 lineage
Uirusu. 2021;71(1):19-32. doi: 10.2222/jsv.71.19.ABSTRACTCoronavirus disease 2019（COVID-19）is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）．It had been first identified in Wuhan at the end of 2019 and the spread of SARS-CoV-2 variants has become a crucial issue worldwide. WHO categorized SARS-CoV-2 variants as "Variants of Concern; VOCs" and "Variants of Interest; VOIs" based on transmissibility, disease severity or their susceptibility to vaccines. Especially, the spread of SARS-CoV-2 variant categorized in VOCs, such as B.1.1.7 and B.1.617.2, has...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Sayaka Sukegawa Hiroaki Takeuchi Source Type: research
Dengue amidst COVID-19: challenges & amp; control measures for the double burden
Uirusu. 2021;71(1):1-10. doi: 10.2222/jsv.71.1.ABSTRACTDengue, an arbovirus, is a public health treat in the tropics and sub-tropical climates worldwide. The disease incidence has grown dramatically worldwide, with an estimated 390 million dengue virus infection per year. Dengue has distinct epidemiological patterns which are associated with the four virus serotypes. All four serotypes can co-circulate within a region, in which a number of regions are hyperendemic for all 4 serotypes. Currently, there are no specific treatment or vaccine for the disease. Dengue prevention depends on vector control measures and early interv...
Source: Uirusu. Journal of Virology - May 8, 2022 Category: Virology Authors: Meng Ling Moi Source Type: research
